Education Center

CME: Current Treatment Strategies for Advanced Prostate Cancer


Click here to read the supplement .

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

  • Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
  • Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
  • Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
  • Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

Click here to read the supplement.

After reading, take the posttest evaluation at

Next Article: